

Prenatal-onset GBS (POGBS) Sepsis is a Distinct Cause of Stillbirth and Perinatal Mortality

James A. McGregor, Marti Perhach
Group B Strep International

ABSTRACT

Background/Introduction

Intrauterine infection is increasingly recognized as a possibly preventable cause of stillbirth (SB). (McClure, Goldenberg. *Semin Fetal Neonatal Med* 2009, 14(4):182-9.)

Methods

Logic model analysis:

- 1) Conduct an expert systematic review and analysis of group B strep (GBS) disease knowledge in order to justify recognition of distinct Prenatal-onset GBS (POGBS) sepsis, distinct from Early-onset (EO) and Late-onset (LO) GBS infection.
- 2) To correlate patient experiences, we conducted a quasi-experimental "internet commons" inquiry of parent contacts who had suffered GBS SB.
- 3) Computer-based national data bases were utilized to assess knowledge of GBS infectious disease.
- 4) An English-language seven-question patient survey was constructed, pretested, and disseminated to selected Group B Strep International contacts using the internet. No written consent was obtained.

Results

Much is known about GBS disease. Despite this knowledge, preventative regimes remain inconsistently applied, and in the best of circumstances are incompletely (85-90%) successful in reducing early-onset GBS infection and do not address late-onset or prenatal-onset GBS infections.

Conclusion

- 1) There is sufficient knowledge to support the CDC proposed (MMWR 2010, Volume 59/RR-10) classification of prenatal-onset GBS POGBS sepsis as a distinct entity.
- 2) Our limited, uncontrolled investigation supports clinical notions that a) GBS loss or SB occurs in a bimodal gestational time distribution with the preponderance of cases occurring near term (POGBS); and b) that mothers do not reliably demonstrate fever or "textbook" findings of potentially lethal intrauterine infection. Other observations are precluded by the limited, uncontrolled nature of our retrospective, self-reported sample.

BACKGROUND

Group B streptococcus (GBS) was identified as a leading cause of perinatal infection in the 1970s.

The prevalent "dogma" is that GBS exposure and subsequent infection occurs only during passage through the GBS colonized birth canal. This notion is the basis of the present CDC-P, ACOG and AAP guidelines to prevent GBS Early-onset Sepsis (EOS).

Non-congruent observations by Katz and more recently Tudela, Wendel, and Sheffield suggest that GBS infection also occurs before birth across intact fetal membranes and causes both stillbirth (SB) and perinatal depression (PD) with depressed Apgars and neonatal death.

Systematic epidemiologic investigations may allow for investigations to possibly reduce risks of pre-labor onset of GBS infections.

GOALS

- 1) Review and Analyze prior observations including:
 - a) Animal models
 - b) Microbiologic findings
 - c) Microbiologic
 - d) Immunologic
 - e) Clinical experimentations which can justify naming "prenatal-onset of early GBS neonatal infection (PO-GBS-EOS)
- 2) Provide rationale for expanded epidemiologic studies
- 3) Suggest strategies which may reduce risks of PO-GBS-EOS

METHODS

- 1) Review/Analyze available information justifying "official" designation of prenatal-onset GBS infections
- 2) Evaluate this proposal using historical "causal criteria," i.e., Kock's postulates & Bradford Hill causal criteria
- 3) Apply pathophysiologic principles including innate and acquired immunologic prevention strategies (i.e., vaccination, microecologic, and clinical strategies to reduce risk of perinatal GBS infection including SB (20-28 weeks) and very early PTB and/or late miscarriage (16-20 weeks)

RESULTS

- 1) Prenatal-onset GBS intrauterine infection has been previously described (Katz, Tudela, Benirschke, others)
- 2) GBS is the commonest or among the commonest microorganisms isolated from normally "sterile" sites after passage through the vagina, between membranes, within placenta, cord blood, heart blood or spleen at autopsy.
- 3) GBS demonstrates pathophysiologic virulence capacities which can explain:
 - a) Intrauterine infection with intact fetal membranes
 - b) Invasive fetal infection
 - c) Lethal factors (toxins, NETs, others) leading to placental or fetal death
 - d) Multiple studies/analysis demonstrate feasibility and practicability of **ACTIVE GBS VACCINATION**

CONCLUSIONS

- 1) GBS, similar to other "perinatal pathogens," is an apparent cause of intrauterine infection (1° chorioamnionitis "CAM" or intraamniotic infection "IAI" can cause SB and very early PTB and possibly LM
- 2) Intrauterine infection or prenatal-onset GBS may explain GBS selective culture-based antibiotic chemoprophylaxis (IAP)
- 3) Recognition of PO-GBS-EOS can allow renewed experimentation in order to further reduce risks of GBS perinatal disease including rapid "Point of Care" microbial testing as well as adjuvant VACCINATION or other novel strategies

RECOMMENDATIONS

- 1) Reconvene well-funded national study group to explore novel strategies to further reduce risk of GBS neonatal disease burden
- 2) These strategies can be separate or in combination with culture-guided IAP:
- 3) VACCINATION
- 4) Microecologic
- 5) Clinical Strategies - screen UTI/ASB
- 6) Further refine microbials screening, i.e., early in pregnancy, UTI/ASB, and in labor or after ROM
- 7) Improve operational procedures to enhance efficacy of IAP

REFERENCES

- Katz VL. Management of group B streptococcal disease in pregnancy. *Clin Obstet Gynecol* 1993;36(4):832-42.
- Tudela CM, Stewart RD, Roberts SW, Wendell GD. Intrapartum evidence of early-onset GBS. *Obstet Gynecol* 2012;119:626-9.
- Colburun T, Assebury C, Bojke L, Phillips Z, Claxton K, Adea AE, Gilbert RE. Prenatal screening and treatment to prevent group B streptococcus and other infection in early infancy: cost effectiveness and value. *Health Technology Assessment* 2007;11.29 p-1-111
- Goins WP, Talbot TR, Schaffner W, Schrag SJ, Griffin MR. Adherence to perinatal group B streptococcal prevention. *Obstet Gynecol* 2010;115:1217-24
- Bang AT, Bang RD, Baitile SB, Reddy MH. Effect of home based neonatal care and management of sepsis on neonatal mortality. *Lancet* 1999;354:1955-1961.
- Mullany LC, Darmstadt CL, Khatri SK, et al. Topical applications of chlorhexidine to the umbilical cord for prevention of omphalitis and neonatal mortality in South Nepal. *Lancet* 2006;367:916-919
- Lamen K, Roy E, Avifeen SE. Effectiveness of maternal influenza immunization in mothers and infants. *NEJM* 2008;359:1555-1564.
- Zaid EA. New Approaches to Preventive Diagnosing and treating neonatal sepsis. *PLOS Med* 7@1000213
- Sinha A, Lieut A, Paoletti LX, Weinstein MC. The projected health benefits of maternal GBS maternal vaccination in the era of chemoprophylaxis. *Vaccine* 23;3197-3195
- Stevens DY, Petri CR, Obborn JL. Enabling a microfluidic immunoassay for the developing world. *Lab Chapter 8*. 2008;2039-2045.
- Healy CM, Baker CJ. Maternal immunization. *Ped Inf Dis J*. 2007;26:945-48.
- Jimenez-Alcazar M, et al. Jhost DNases prevent vascular occlusion by neutrophil extracellular traps. *Science*. 2017, Dec 1;358(6367):1202-1206.



Kyle & Kian



Solomon



Carissa



Jaxton